RT Journal Article
SR Electronic
T1 Kinetics of viral clearance and antibody production across age groups in SARS-CoV-2 infected children
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.06.20162446
DO 10.1101/2020.08.06.20162446
A1 Bahar, Burak
A1 Jacquot, Cyril
A1 Mo, Yunchuan D.
A1 DeBiasi, Roberta L.
A1 Campos, Joseph
A1 Delaney, Meghan
YR 2020
UL http://medrxiv.org/content/early/2020/08/07/2020.08.06.20162446.abstract
AB Objectives To improve understanding of transition from viral infection to viral clearance, and antibody response in pediatric patients with SARS-CoV-2 infection.Study design This retrospective analysis of children tested for SARS-CoV-2 by RT-PCR and IgG antibody at a quaternary-care, free-standing pediatric hospital between March 13th, 2020 to June 21st, 2020 included 6369 patients who underwent PCR testing and 215 patients who underwent antibody testing. During the initial study period, testing focused primarily on symptomatic children; the later study period included asymptomatic patients who underwent testing as preadmission or preprocedural screening. We report the proportion of positive and negative tests, time to viral clearance, and time to seropositivity.Results The rate of positivity varied over time due to viral circulation in the community and transition from targeted testing of symptomatic patients to more universal screening of hospitalized patients. Median duration of viral shedding (RT-PCR positivity) was 19.5 days and RT-PCR negativity from positivity was 25 days. Of note, patients aged 6 to 15 years demonstrated a longer period of RT-PCR negativity from positivity, compared to patients aged 16 to 22 years (median=32 versus 18 days, p=0.015). Median time to seropositivity from RT-PCR positivity was 18 days while median time to reach adequate levels of neutralizing antibodies (defined as equivalent to 160 titer) was 36 days.Conclusions The majority of patients demonstrated a prolonged period of viral shedding after infection with SARS CoV-2. Whether this correlates with persistent infectivity is unknown. Only 17 of 33 patients demonstrated neutralizing antibodies, suggesting that some patients may not mount significant immune responses to infection. It remains unknown if IgG antibody production correlates with immunity and how long measurable antibodies persist and protect against future infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was submitted to institutional IRB review and received approval for a QA/QI type project. Per the IRB evaluation: "Based on the information submitted, this is a project undertaken as a Quality Improvement Initiative at Childrens National and does not constitute human subjects research. As such the project does not require oversight by the IRB.” This project and manuscript was also evaluated and approved by the Childrens National Hospital COVID-19 publication review committee. Data were anonymized by merging medical record numbers and sample container IDs. Data were extracted from our laboratory information systems data warehouse (Sunquest Information Systems Database [Tucson, AZ, USA] and Vertica Analytics Platform [Cambridge, MA]) using Viewics Analytics Platform (Roche, Indianapolis, IN) with Structured Query Language (SQL) queries. Extracts were merged into CSV files and imported into RStudio IDE (Boston, MA) for analysis. Data were stored in encrypted drives.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data would be provided upon request after approval from institutional approval.